For the third quarter of 2026, analysts expect LENZ Therapeutics to report revenue of $4.20 million and a consensus EPS of -$0.97, with the stock currently trading at $3.16 against an average price target of $22.14.
Investors are primarily focused on the commercial traction and prescription growth of VIZZ (aceclidine 1.44%), the company's first FDA-approved eye drop for presbyopia.
This quarter marks a critical phase in the product's first full year of launch, following a successful Q2 where the company surpassed revenue expectations. While recent price target adjustments by some firms reflect short-term volatility, consensus remains bullish on the long-term potential of the aceclidine-based platform.